866-997-4948(US-Canada Toll Free)

Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026

Published By :

GlobalData

Published Date : Mar 2018

Category :

Pharmaceutical

No. of Pages : 272 Pages

Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2026

Summary

The head and neck (HNC) cancer market is expected to experience significant growth between 2016 and 2026 within the seven major markets (US, France, Germany, Italy, Spain, UK and Japan). The main growth drivers will be attributed to the incorporation of immune-checkpoint inhibitors into the first-line recurrent/metastatic and locally-advanced disease treatment paradigms. Due to the high cost of immunotherapy regimens, this is expected to cause large growth within the head and neck cancer market.

Up until the approvals of Opdivo in the 7MM and Keytruda in the US during 2016 for the platinum-refractory recurrent/metastatic population, Erbitux was the only targeted agent ion the market, whilst the rest of the market was dominated by generic chemotherapy. Now that programmed cell death protein 1 (PD-1) inhibitors have penetrated into the second-line, label-expansions into earlier lines and in combinations with other immuno-oncology (IO) agents are expected during the forecast period. This will significantly expand the eligible population that can receive these premium-priced immunotherapies - The HNC competitive landscape is expected to experience a significant change, a new standard of care is predicted to be established in eight pipeline agents are expected to launch before 2026.

Key Questions Answered

- How will the implementation of IO agents into earlier-lines of therapy affect the current treatment paradigm and which combinations are expected to have the greatest impact and highest chance of an approval?
- The head and neck cancer market is characterized by a number of unmet needs. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these needs?
- Eight late-stage pipeline agents are going to enter the head and neck cancer market from 2017 onwards. Will the late-stage drugs make a significant impact on the head and neck cancer market? Which of these drugs will have the highest peak sales, and why?

Scope

- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
- Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized HNC therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2016 to 2026.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HNC market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HNC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Executive Summary 11
2.1 Dramatic Growth Is Projected for the 7MM HNSCC Market from 2016 to 2026 12
2.2 Immuno-oncology Drugs to Extend Their Reach to All HNSCC Market Segments 15
2.3 High Unmet Needs for Biomarker of Response in the HNSCC Market 16
2.4 Opportunities Remain for Developers Who Launch Novel Treatments for HNSCC Subpopulations and Identify New Druggable Targets 17
2.5 What Do the Physicians Think? 17
3 Introduction 20
3.1 Catalyst 20
3.2 Related Reports 21
3.3 Upcoming Related Reports 21
4 Disease Overview 22
4.1 Etiology and Pathophysiology 22
4.1.1 Etiology 22
4.1.2 Pathophysiology 25
4.1.3 Biomarkers 26
4.2 Clinical Staging 29
4.3 Symptoms 38
4.4 Prognosis 39
4.5 Quality of Life 40
5 Epidemiology 41
5.1 Disease Background 41
5.2 Risk Factors and Comorbidities 42
5.3 Global and Historical Trends 44
5.4 Forecast Methodology 47
5.4.1 Sources 48
5.4.2 Forecast Assumptions and Methods - Population 53
5.4.3 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNCs 53
5.4.4 Forecast Assumptions and Methods - Five-Year Diagnosed Prevalent Cases of HNCs 58
5.4.5 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNCs by Histology Distribution 59
5.4.6 Forecast Assumptions and Methods - Diagnosed Incident Cases of HNC by Clinical Stages at Diagnosis for Squamous Cell Carcinoma 60
5.4.7 Forecast Assumptions and Methods - Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-) 61
5.4.8 Forecast Assumptions and Methods - Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+) 61
5.5 Epidemiological Forecast for HNCs (2016-2026) 62
5.5.1 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer 62
5.5.2 Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer 63
5.5.3 Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer 64
5.5.4 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution 65
5.5.5 Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma 65
5.5.6 Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer 66
5.5.7 Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV) 67
5.5.8 Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV) 68
5.5.9 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer 69
5.5.10 Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer 70
5.5.11 Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer 71
5.5.12 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution 72
5.5.13 Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma 73
5.5.14 Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer 74
5.6 Discussion 75
5.6.1 Epidemiological Forecast Insight 75
5.6.2 Limitations of the Analysis 76
5.6.3 Strengths of the Analysis 77
6 Current Treatment Options 78
6.1 Overview 78
6.2 Diagnosis and Treatment 80
6.2.1 Diagnosis 80
6.2.2 Treatment Guidelines and Leading Prescribed Drugs 81
6.3 Clinical Practice 82
6.3.1 Overview 82
6.4 Product Profiles 85
6.4.1 Opdivo (Nivolumab) 87
6.4.2 Keytruda (Pembrolizumab) 93
6.4.3 Erbitux (Cetuximab) 102
6.4.4 TS-1 (Tegafur + Gimeracil + Oteracil) 111
6.5 Standard of Care Chemotherapy Review 114
6.5.1 Cisplatin 114
6.5.2 Docetaxel 116
6.5.3 Fluorouracil (5-FU) 117
6.5.4 Methotrexate 118
6.6 Other Therapeutic Classes 118
7 Unmet Needs Assessment and Opportunity Analysis 119
7.1 Overview 119
7.1.1 Less Aggressive 1L Treatments for rmHNSCC 120
7.1.2 Curative Intent Treatments for LA-HNSCC in the Adjuvant and Induction Settings 123
7.1.3 More Effective Treatments for HPV-Negative Disease 125
7.1.4 De-intensified Treatments for the HPV-Positive HNC Cohorts 127
7.1.5 Innovative Treatments for Rare Head and Neck Cancer Sites 128
7.1.6 Predictive Biomarkers to Guide and Improve the Current Treatments in Use 130
8 R&D Strategies 134
8.1 Overview 134
8.1.1 Identification of Predictive Biomarker of Response to Immunotherapies 135
8.1.2 Immunotherapy Combinations for rmHNSCC 136
8.1.3 Immunotherapies Move in the Untapped LA-HNSCC Setting 137
8.1.4 Evaluating More Potent, Highly Selective Kinase Inhibitors 138
8.1.5 Precision Medicine in Head and Neck Cancer 139
8.2 Clinical Trial Design 140
8.2.1 Overall Survival Remains Most Important Outcome for rmHNSCC 144
8.2.2 Multi-Arm Trials Becoming More Common in the Head and Neck Pipeline 146
8.2.3 Future Trial Design: Active Comparator Issue 147
9 Pipeline Assessment 148
9.1 Overview 148
9.2 Drugs in Late-Stage Clinical Development 150
9.3 Chemotherapies 151
9.3.1 Javlor (Vinflunine) 151
9.4 Kinase Inhibitors 156
9.4.1 Gilotrif (Afatinib) 156
9.5 Immunotherapies 160
9.5.1 Multikine (Leukocyte Interleukin) 160
9.5.2 TT-10 (Virus-Specific T-Cell Therapy) 164
9.6 Immune Checkpoint Modulators 169
9.6.1 Imfinzi (durvalumab) 170
9.6.2 Tecentriq (atezolizumab) 176
9.6.3 Bavencio (avelumab) 179
9.6.4 Yervoy (ipilimumab) 184
9.6.5 Tremelimumab 188
9.6.6 Epacadostat 192
9.7 Innovative Early-Stage Approaches 199
9.7.1 Immunotherapies - Combinations and New Targets 201
9.7.2 Kinase Inhibitors - Label Expansion and Continued Development 202
9.7.3 Adoptive T-Cell Therapies and Immune-Stimulants 203
9.7.4 Therapeutic Vaccines and Oncolytic Viruses 204
9.7.5 Other Therapies in Development 205
10 Pipeline Valuation Analysis 207
10.1 Clinical Benchmark of Key Pipeline Drugs 207
10.2 Commercial Benchmark of Key Pipeline Drugs 212
10.3 Competitive Assessment 215
10.4 Top-Line 10 Year Forecast 217
10.4.1 US 223
10.4.2 5EU 225
10.4.3 Japan 227
11 Appendix 229
11.1 Bibliography 229
11.2 Abbreviations 243
11.3 Methodology 250
11.4 Forecasting Methodology 250
11.4.1 Diagnosed Head and Neck Cancer Patients 250
11.4.2 Percent Drug-Treated Patients 251
11.4.3 Drugs Included in Each Therapeutic Class 251
11.4.4 Launch and Patent Expiry Dates 252
11.4.5 General Pricing Assumptions 253
11.4.6 Individual Drug Assumptions 254
11.5 Primary Research 264
11.5.1 Physicians and Specialists Included in This Study 264
11.5.2 Online Survey of High-Prescribing Physicians 266
11.6 About the Authors 267
11.6.1 Analysts 267
11.6.2 Therapy Area Director 267
11.6.3 Epidemiologist 268
11.6.4 Reviewers 268
11.6.5 Global Director of Therapy Analysis and Epidemiology 269
11.7 About GlobalData 271
11.8 Contact Us 271
11.9 Disclaimer 272

1.1 List of Tables
Table 1: Head and Neck Squamous Cell Carcinoma: Key Metrics in the Seven Major Pharmaceutical Markets, 2016-2026 11
Table 2: ICD-10 Codes Used to Classify HNCs 23
Table 3: HNC Locations and Their Clinically Defined Descriptions 25
Table 4: Comparison of Different Biomarkers with Potential in HNSCC 28
Table 5: TNM Classification of Lip, Oral Cavity, and Oropharyngeal Cancers 30
Table 6: TNM Classification of the Larynx 31
Table 7: TNM Classification of the Hypopharynx 33
Table 8: TNM Classification of Nasal Cavity and Paranasal Sinus Cancers 34
Table 9: TNM Classification of Salivary Gland Cancers 36
Table 10: TNM Classification of Nasopharyngeal Cancers 37
Table 11: Stage Grouping for HNC (Excluding Nasopharyngeal Cancer) 38
Table 12: Stage Grouping for Nasopharyngeal Cancer 38
Table 13: Symptoms of HNSCC 39
Table 14: Risk Factors and Comorbid Conditions Associated with HNCs 43
Table 15: 7MM, Diagnosed Incident Cases of Oropharynx Cancer by Histology Distribution and by Risk Factor (HPV), Both Sexes, Ages 18 Years, N, 2016 68
Table 16: 7MM, Diagnosed Incident Cases of Nasopharynx Cancer by Histology Distribution and by Risk Factor (EBV+), Both Sexes, Ages 18 Years, N, 2016 69
Table 17: Leading Treatments for HNCs 80
Table 18: Treatment Guidelines for HNSCC 81
Table 19: Most Prescribed Drugs for HNSCC by Class in the Global Markets, 2016 82
Table 20: Product Profile - Opdivo 88
Table 21: Ongoing Clinical Trials of Opdivo 90
Table 22: Efficacy of Opdivo versus Investigators Choice, CheckMate-141 91
Table 23: Safety of Opdivo in rmHNSCC 92
Table 24: Opdivo SWOT Analysis 93
Table 25: Product Profile - Keytruda 95
Table 26: Ongoing Clinical Trials of Keytruda 98
Table 27: Efficacy of Keytruda, Phase Ib KEYNOTE-012 Expansion Cohort 99
Table 28: Safety of Keytruda, KEYNOTE-012 Phase Ib trial 101
Table 29: Keytruda SWOT Analysis 102
Table 30: Product Profile - Erbitux 104
Table 31: Efficacy of Erbitux with Cisplatin and 5-FU in rmHNSCC Patients, in a Phase III, Randomized, Open-Label Trial 105
Table 32: Efficacy of Erbitux with Radiotherapy in LA-HNSCC in a Phase III, Randomized, Open-Label Trial 106
Table 33: Safety of Erbitux with Cisplatin and 5-FU Chemotherapy in rmHNSCC 108
Table 34: Erbitux SWOT Analysis 109
Table 35: Product Profile - TS-1 112
Table 36: Safety of TS-1 Monotherapy in Patients with rmHNSCC 113
Table 37: TS-1 SWOT Analysis 114
Table 38: Summary of Additional Chemotherapy Agents Used for HNSCC in 2016 118
Table 39: Phase III Trials for rmHNSCC 142
Table 40: Key Phase III Trials for LA-HNSCC 144
Table 41: Head and Neck Squamous Cell Carcinoma - Late Stage Pipeline, 2018 151
Table 42: Product Profile - Javlor 153
Table 43: Efficacy of Javlor with Methotrexate in rmHNSCC from the Single Arm, Phase I, Dose-Finding Trial 154
Table 44: Safety of Javlor with Methotrexate in rmHNSCC from a Single Arm, Phase I, Dose-Finding Trial 155
Table 45: Javlor SWOT Analysis 155
Table 46: Product Profile - Gilotrif 157
Table 47: Efficacy of Gilotrif with Methotrexate in rmHNSCC 158
Table 48: Safety of Gilotrif with Methotrexate in rmHNSCC (NCT01345682) 159
Table 49: Gilotrif SWOT Analysis 160
Table 50: Product Profile - Multikine (interleukin injection) 162
Table 51: Multikine SWOT Analysis 164
Table 52: Product Profile - TT-10 166
Table 53: Efficacy of TT-10 from Phase II Trials, Chemotherapy Plus EBV VSTs in NPC Patients 167
Table 54: TT-10 SWOT Analysis 169
Table 55: Product Profile - Imfinzi 171
Table 56: Ongoing Early-Stage Clinical Trials of Imfinzi 173
Table 57: Efficacy of Imfinzi in rmHNSCC PD-L1-Positive Patients (Phase II HAWK Study) 174
Table 58: Efficacy of Imfinzi and Tremelimumab in rmHNSCC PD-L1-Negative or Low Patients (Phase II CONDOR Study) 175
Table 59: Imfinzi SWOT Analysis 176
Table 60: Product Profile - Tecentriq 177
Table 61: Tecentriq SWOT Analysis 179
Table 62: Product Profile - Bavencio 181
Table 63: Safety Profile of Bavencio Based On the JAVELIN Solid Tumor Trial for Patients with Locally Advanced or Metastatic UC 183
Table 64: Bavencio SWOT Analysis 184
Table 65: Product Profile - Yervoy 186
Table 66: Yervoy SWOT Analysis 188
Table 67: Product Profile - Tremelimumab 189
Table 68: Tremelimumab SWOT Analysis 192
Table 69: Product Profile - Epacadostat 193
Table 70: Ongoing Clinical Trials of Epacadostat 195
Table 71: Efficacy of Epacadostat in Combination with Opdivo from the HNC Cohort, ECHO-204 Trial 196
Table 72: Efficacy of Epacadostat in Combination with Keytruda from the HNC cohort, ECHO-202 Trial 197
Table 73: Safety of Epacadostat, ECHO-204 198
Table 74: Epacadostat SWOT Analysis 199
Table 75: Innovative Early-Stage Pipeline Therapies Head & Neck Cancer, 2018 200
Table 76: Other Early-Stage Drugs in Development for HNC, 2018 206
Table 77: Clinical Benchmark of Pipeline Drugs - IO Therapies 208
Table 78: Clinical Benchmark of Pipeline Drugs - Non-IO 208
Table 79: Commercial Benchmark of Pipeline Drugs - IO Agents 213
Table 80: Commercial Benchmark of Pipeline Drugs - Non-IO 214
Table 81: Key Events Impacting Sales for HNSCC 222
Table 82: HNSCC Market - Drivers and Barriers, 2016-2026 223
Table 83: Key Historical and Projected Launch Dates, 2016-2026 252
Table 84: High-Prescribing Physicians Surveyed, by Country 266

1.2 List of Figures
Figure 1: Sales for HNSCC Therapeutics by Region, 7MM, 2016-2026 14
Figure 2: Competitive Assessment of Marketed and Pipeline HNSCC Agents, 2016-2026 16
Figure 3: Anatomical Sites of HNCs 22
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, Pharynx, and Larynx Cancer (Cases per 100,000 Population), Men, Ages 18 Years, 2016-2026 45
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of Lip, Oral Cavity, Pharynx, and Larynx Cancer (Cases per 100,000 Population), Women, Ages 18 Years, 2016-2026 45
Figure 6: 7MM, Age-Standardized Diagnosed Incidence of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (Cases per 100,000 Population), Men, Ages 18 Years, 2016-2026 46
Figure 7: 7MM, Age-Standardized Diagnosed Incidence of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer (Cases per 100,000 Population), Women, Ages 18 Years, 2016-2026 47
Figure 8: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer; Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer 48
Figure 9: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer; Oropharynx Cancer; Nasopharynx Cancer by Histology Distribution 49
Figure 10: 7MM, Sources Used, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution 49
Figure 11: 7MM, Sources Used, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma 50
Figure 12: 7MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer; Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma 50
Figure 13: 7MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer 51
Figure 14: 7MM, Sources Used, Five-Year Diagnosed Prevalent Cases of Nasopharynx Cancer; Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer 51
Figure 15: 7MM, Sources Used, Diagnosed Incident Cases of Oropharynx Cancer by Risk Factor (HPV+ and HPV-) 52
Figure 16: 7MM, Sources Used, Diagnosed Incident Cases of Nasopharynx Cancer by Risk Factor (EBV+) 52
Figure 17: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, Ages 18 Years, N, 2016 62
Figure 18: 7MM, Age-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, N, 2016 63
Figure 19: 7MM, Sex-Specific Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Ages 18 Years, N, 2016 64
Figure 20: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Histology Distribution, Both Sexes, Ages 18 Years, N, 2016 65
Figure 21: 7MM, Diagnosed Incident Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma, Both Sexes, Ages 18 Years, N, 2016 66
Figure 22: 7MM, Five-Year Diagnosed Prevalent Cases of Lip, Oral Cavity, Pharynx, and Larynx Cancer, Both Sexes, Ages 18 Years, N, 2016 67
Figure 23: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages 18 Years, N, 2016 70
Figure 24: 7MM, Age-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related StructuresCancer, Both Sexes, Ages 18 Years, N, 2016 71
Figure 25: 7MM, Sex-Specific Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Ages 18 Years, N, 2016 72
Figure 26: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer by Histology Distribution, Both Sexes, Ages 18 Years, N, 2016 73
Figure 27: 7MM, Diagnosed Incident Cases of Salivary Gland and Nose, Sinuses, and Other Related StructuresCancer by Clinical Stage at Diagnosis for Squamous Cell Carcinoma, Both Sexes, Ages 18 Years, N, 2016 74
Figure 28: 7MM, Five-Year Diagnosed Prevalent Cases of Salivary Gland and Nose, Sinuses, and Other Related Structures Cancer, Both Sexes, Ages 18 Years, N, 2016 75
Figure 29: Treatment Overview in HNSCC Patients 83
Figure 30: Treatment Overview in Nasopharyngeal Carcinoma Patients 84
Figure 31: Opdivos Development in HNSCC 89
Figure 32: Keytrudas Development in HNSCC 97
Figure 33: Unmet Needs and Opportunities in HNC 120
Figure 34: Overview of the Development Pipeline in HNSCC 149
Figure 35: HNSCC Phase III Pipeline in Development for the 7MM, 2016-2026 150
Figure 36: Javlors Development in HNSCC 154
Figure 37: Gilotrifs Development in HNSCC 158
Figure 38: Multikines Development in HNSCC 163
Figure 39: TT-10s Development in HNSCC 167
Figure 40: Imfinzis Development in HNSCC 172
Figure 41: Tecentriqs Development in HNSCC 178
Figure 42: Bavencios Development in HNSCC 182
Figure 43: Yervoys Development in HNSCC 187
Figure 44: Tremelimumabs Development in HNSCC 190
Figure 45: Epacadostats Development in HNSCC 195
Figure 46: Competitive Assessment of Marketed and Pipeline HNSCC Agents, 2016-2026 217
Figure 47: Sales for HNC Products by Region, 2016-2026 220
Figure 48: Sales for HNC Products by Drug Class, 2016-2026 221
Figure 49: Sales for HNC Products by Drug Class in the US, 2016-2026 224
Figure 50: Sales for HNC Products by Drug Class in the 5EU, 2016-2026 226
Figure 51: Sales for HNC Products by Drug Class in Japan, 2016-2026 228

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *